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Overexpression of Sphingosine Kinase 1 Prevents
Ceramide Accumulation and Ameliorates Muscle
Insulin Resistance in High-Fat Diet–Fed Mice
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Ahrathy Selathurai,2 Robert S. Lee-Young,1 Jacquelyn M. Weir,3 Kazuaki Yoshioka,4 Yoh Takuwa,4
Peter J. Meikle,3 Stuart M. Pitson,5 and Mark A. Febbraio1
The sphingolipids sphingosine-1-phosphate (S1P) and ceramide
are important bioactive lipids with many cellular effects. In-
tracellular ceramide accumulation causes insulin resistance, but
sphingosine kinase 1 (SphK1) prevents ceramide accumulation,
in part, by promoting its metabolism into S1P. Despite this, the
role of SphK1 in regulating insulin action has been largely
overlooked. Transgenic (Tg) mice that overexpress SphK1 were
fed a standard chow or high-fat diet (HFD) for 6 weeks before
undergoing several metabolic analyses. SphK1 Tg mice fed an
HFD displayed increased SphK activity in skeletal muscle, which
was associated with an attenuated intramuscular ceramide
accumulation compared with wild-type (WT) littermates. This
was associated with a concomitant reduction in the phosphory-
lation of c-jun amino-terminal kinase, a serine threonine kinase
associated with insulin resistance. Accordingly, skeletal muscle
and whole-body insulin sensitivity were improved in SphK1 Tg,
compared with WT mice, when fed an HFD. We have identiﬁed
that the enzyme SphK1 is an important regulator of lipid
partitioning and insulin action in skeletal muscle under condi-
tions of increased lipid supply. Diabetes 61:3148–3155, 2012
Obesity is associated with the development ofinsulin resistance and type 2 diabetes. Thepathogenesis of insulin resistance is a well-investigated area, yet the precise interplay be-
tween the molecular pathways that leads to this disorder is
not fully understood (1). Extensive evidence, however,
suggests that defects in fatty acid (FA) metabolism and
subsequent lipid accumulation in liver and skeletal muscle
play a major role (2,3). Although the increase in lipid
manifests as an increase in triacylglycerol (TAG), it is
likely that this is a marker of dysfunctional FA metabolism
and that accumulation of bioactive lipids, such as ceram-
ide and diacylglycerol (DAG), impair insulin action. DAG
accumulation in muscle is associated with insulin resistance
in humans (4), whereas mice with DAG kinase delta haplo-
insufﬁciency display increased DAG content and reduced
peripheral insulin sensitivity (5).
Ceramide is a potent lipid-signaling molecule that can
cause insulin resistance by inhibiting the ability of insulin
to activate Akt (6) and/or via the activation of c-jun amino
terminal kinase (JNK) (7,8). Importantly, preventing
ceramide accumulation by inhibiting de novo ceramide
synthesis protects against the development of insulin re-
sistance (9,10). These observations support the hypothesis
that increases in ceramide are an important mechanism
underlying the development of muscle insulin resistance,
and therefore, targeting pathways to prevent ceramide
accumulation may be a viable therapeutic approach.
One such approach is to increase ceramide degradation
and clearance. Two important enzymes in this pathway are
ceramidase and sphingosine kinase (SphK). Ceramidase is
responsible for converting ceramide to sphingosine, and
SphK phosphorylates sphingosine to sphingosine 1 phos-
phate (S1P). Because breakdown of S1P is the only way
for cellular lipids to exit the sphingolipid pathway, SphK is
important in regulating sphingolipid metabolism (11).
SphK exists in two isoforms, SphK1 and SphK2. Despite
clear evidence that SphK1 activation reduces ceramide
(12,13), the role of SphK1 in regulating insulin action has
been largely overlooked. Activation of SphK1 prevents
ceramide accumulation by promoting its metabolism into
S1P. SIP is a molecule with many complex functions: it not
only activates ﬁve speciﬁc G-coupled protein receptors
that subsequently activate many downstream signaling
pathways but also has important second messenger
actions (14). SIP is generally thought to promote activation
of inhibitor of k kinase-b (IKK-b) and JNK via upstream
activation of transforming growth factor-b–activated ki-
nase 1 (14), however, SphK1 can block JNK activation
(13,15) and prevent tissue inﬂammation (15), which is
linked to insulin resistance (16). In contrast, inhibiting
SphK1 leads to JNK activation (17). Interestingly, S1P itself
opposes the effects of ceramide. For example, S1P has
been shown to counteract ceramide-induced activation of
JNK (18). Thus, it has been proposed that the ceramide-to-
S1P ratio may function as an intracellular rheostat (19,20).
Although not well studied in the context of metabolic
disease, evidence is emerging to suggest that the sphin-
golipid rheostat is important in regulating insulin action.
Adiponectin has been thought to exert insulin-sensitizing
effects via activation of AMP-activated protein kinase
(AMPK) (21). However, Scherer and colleagues (22) re-
cently provided compelling evidence that adiponectin, by
stimulating ceramidase activity, decreases intracellular
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ceramide and concomitantly increases S1P. Hence, the
dynamic balance between the levels of ceramide and S1P
may have implications for the development of obesity-
induced insulin resistance. The aim of the current study
was, therefore, to examine the role of SphK in regulating
skeletal muscle ceramide content and insulin sensitivity
in conditions of lipid oversupply. We hypothesized that
SphK1 overexpression would promote ﬂux through the
sphingolipid degradative pathway, which would prevent
high-fat diet (HFD)–induced ceramide accumulation and,
therefore, enhance muscle insulin action.
RESEARCH DESIGN AND METHODS
Animals. All experimental procedures were approved by the Alfred Medical
Research and Education Precinct Animal Ethics Committee and were in ac-
cordance with the National Health and Medical Research Council (NHMRC) of
Australia Guidelines on Animal Experimentation. Generation of the moderate-
level or low-level SphK1a transgenic (SphK1 Tg) mice has been described
elsewhere (23,24). Mice were maintained on a C57Bl/6 background (back-
crossed $9 times). All experiments commenced when mice were 8 weeks old.
Male SphK1 Tg mice and their wild-type (WT) littermates were kept in
a temperature controlled room (22 6 1°C) on a 12-h light/dark cycle with free
access to food and water. Mice were fed a standard chow diet (14.3 MJ/kg, 76%
of kJ from carbohydrate, 5% fat, 19% protein, Specialty Feeds, Glen Forrest,
Western Australia, Australia). For the fat-feeding studies, mice were fed an
HFD (19 MJ/kg, 35% of kJ from carbohydrate, 42% fat [42.7% saturated, 35.1
monounsaturated and 21.7% polyunsaturated FAs], 23% protein, Specialty
Feeds) for 6 weeks. Lean and fat mass were determined using the EchoMRI
4-in-1 (Echo Medical Systems, Houston, TX).
Mice were randomly assigned to two groups that underwent procedures to
determine 1) skeletal muscle glucose uptake or 2) activation of intracellular
signaling molecules. Glucose tolerance tests were performed on a subset of mice
from each group, and samples of plasma and tissue were collected for sub-
sequent analysis. A separate group of WT and SphK1 Tg mice were fed an HFD
and were studied under hyperinsulinemic clamp conditions (described below).
The numbers for each group are presented in the table and ﬁgure legends.
Glucose tolerance tests. Intraperitoneal glucose tolerance tests (1 g/kg lean
body mass) were performed on mice fasted for 5 h. Blood samples were
obtained from the tail tip at the indicated times, and blood glucose levels were
measured (AccuCheck II; Roche, Castle Hill, New South Wales, Australia).
In vivo electroporation. cDNA encoding the human SphK2 gene was cloned
into the pcDNA3.1 expression vector (25). Plasmids were injected into tibialis
anterior muscles and electroporated by a previously described protocol
(26,27). All experiments were performed 7 days after transfection.
Skeletal muscle incubations. Mice were fasted for 5 h and anesthetized by
injection of sodium pentobarbitone (50 mg/kg i.p.). Glucose uptake in
isolated extensor digitorum longus (EDL) muscle was assayed for 15 min
using [3H]-2-deoxy-D-glucose (1 mmol/L; 0.128 mCi/mL) as described pre-
viously (26). For analysis of insulin signaling, EDL muscles were incubated
in Krebs-Henseleit buffer (pH 7.4), with or without insulin (300 mU/mL) for
30 min.
Hyperinsulinemic, euglycemic clamp. Mice were catheterized 4 days before
hyperinsulinemic, euglycemic clamp studies. Mice were anesthetized with
isoﬂurane (1–2% in oxygen), and the right jugular vein was catheterized with
a Silastic catheter (0.025-inch outer diameter). The catheter was exteriorized
at the back of the neck, ﬁlled with sterile saline, and sealed with a stainless
steel plug. After surgery, animals were individually housed, and body weight
was recorded daily. Hyperinsulinemic, euglycemic clamps were performed on
5-h fasted, conscious, restrained mice. The infusion protocol consisted of
a 150-min tracer equilibration period (t = 2150 to 0 min) beginning at 0830 h,
followed by a 120-min experimental period (t = 0 to 120 min) beginning at
1000 h. A bolus of [3-3H]glucose (5 mCi; PerkinElmer, Waltham, MA) was
administered at t = 2120 min, followed by a constant infusion of 0.05 mCi/min
for 150 min. At t = 215 and 25 min, blood samples (;50 mL) were obtained
from the tail tip for assessment of basal glucose, plasma insulin, and free FAs
(FFAs), as well as glucose-speciﬁc activity. The hyperinsulinemic, euglycemic
clamp was initiated at t = 0 min with an infusion of human insulin (4 mU $ kg21 $
min21; ActRapid; Novo Nordisk, Baulkham Hills, New South Wales, Australia).
To minimize changes in glucose speciﬁc activity, the [3-3H]glucose infusion was
increased to 0.1 mCi/min. Blood glucose was measured every 10 min, and
euglycemia (;10–11 mmol/L) was maintained by infusing 30% dextrose as re-
quired. Blood samples (10 mL) were taken every 10 min from t = 80 to 120 min to
determine glucose-speciﬁc activity. At 120 min, a bolus of 2[14C]deoxyglucose
([14C]2DG; 13 mCi; PerkinElmer, Waltham, MA) was administered via the
catheter. Blood (10 mL) was taken at 2, 15, 25, and 35 min for the de-
termination of [14C]2DG. Mice were then anesthetized and tissues collected.
Plasma insulin and FFA levels were determined from samples obtained from
cardiac puncture on anesthetized mice at the end of the clamp procedure.
Determination of plasma and tissue radioactivity. Blood samples (10 mL)
were deproteinized with barium hydroxide (0.3 N) and zinc sulfate (0.3 N), and
[3-3H]glucose and 2[14C]DG radioactivity was determined by liquid scintillation
counting. The rate of glucose appearance (endogenous Ra) and disappearance
(Rd) were determined using steady-state equations. Endogenous glucose
production during the clamp was calculated by subtracting the glucose in-
fusion rate (GIR) from Rd. The insulin-stimulated component of the total Rd
(IS-Rd) is equal to clamp Rd minus the basal glucose turnover rate. Accumu-
lation of [14C]2DG was determined in an aqueous extract of tissue after ho-
mogenization. Free and phosphorylated [14C]2DG were separated by ion
exchange chromatography on Dowex l-X8 columns (acetate form). The area
under the tracer disappearance curve of [14C]2DG, together with the radio-
activity for the phosphorylated [14C]2DG from individual tissues, were used to
calculate the glucose metabolic index (Rg9) (28).
Western blotting. Tissues were lysed, and protein concentration was de-
termined. Lysates were solubilized, 40 mg protein was loaded and resolved by
SDS-PAGE on polyacrylamide gels, transferred to membranes, and blocked
with 5% milk. Immunoblotting was performed using the following primary
antibodies: phosphorylated (p)Akt serine 473 and total (t)Akt (Cell Signaling
Technology, Danvers, MA), pJNK (Thr183/Tyr185) and tJNK (Cell Signaling
Technology), as well as pIKK-b (Ser181), tIKK-b (Cell Signaling Technology).
After incubation with appropriate secondary antibody, the immunoreactive
proteins were detected with enhanced chemiluminescence and quantiﬁed by
densitometry. Analysis of membrane and cytosolic protein kinase C u (PKCu)
were performed as previously described (26).
Plasma analysis. Plasma insulin was measured by ELISA (Millipore, St. Louis,
MO). FFAs were measured spectrophotometrically by an enzymatic colori-
metric assay (NEFA C kit; Wako Chemicals, Richmond, VA). Plasma triglycerides
were determined using a colorimetric assay kit (Triglycerides GPO-PAP; Roche
Diagnostics, Indianapolis, IN). Plasma S1P concentration was assessed by S1P
ELISA (Echelon, Salt Lake City, UT).
SphK activity and S1P. SphK activity in tissue homogenates was determined
using D-erythro-sphingosine and [g-32P]ATP as substrates, as described pre-
viously (29). Muscle S1P levels were determined using previously described
methods (30).
Lipid analysis. Lipids were extracted from plasma (10 mL) using a single-
phase chloroform/methanol (2:1 v/v) extraction, as previously described (31)
and were analyzed for ceramide content. For tissue lipids (DAG, ceramide,
sphingomyelin, sphingosine, phosphatidylcholine [PC], and phosphatidyleth-
anolamine [PE]), samples were homogenized in 300 mL 1xPBS (pH 7.47), and
protein content was determined. Lipids were extracted from 50 mg protein for
muscle, 10 mg protein for white adipose tissue (WAT) and 25 mg protein for
liver. Lipids were extracted using a single-phase chloroform/methanol (2:1 v/v;
20 volumes) extraction after the addition of internal standards (100 pmol each
of ceramide 17:0, PC 13:0/13:0, PE 17:0/17:0, sphingomyelin 12:0, and sphin-
gosine 17:1; Avanti Polar Lipids, Alabaster, AL), together with 200 pmol DAG
15:0/15:0 (Sigma-Aldrich, St. Louis, MO). Samples were vortexed, mixed for 10
min, sonicated for 30 min, and left at room temperature for 20 min. Extracts
were centrifuged at 13,000g for 10 min. The supernatant was transferred to
a clean tube and dried under nitrogen at 40°C. Lipids were redissolved in
50 mL water-saturated butanol containing 10 mmol/L NH4COOH, then 50 mL
methanol containing 10 mmol/L NH4COOH was added. Analysis was per-
formed by electrospray ionization–tandem mass spectrometry using a PE
Sciex API 4000 Q/TRAP mass spectrometer with a turbo-ionspray source and
Analyst 1.5 data system, as described previously (32). Tissue TAG content was
determined biochemically using a colorimetric assay kit (Triglycerides GPO-
PAP; Roche Diagnostics).
RNA isolation and quantitative real-time RT-PCR. Total RNA was isolated
from gastrocnemius muscle using Trizol (Invitrogen, Carlsbad, CA). Samples
were reverse-transcribed using TaqMan reverse-transcription reagents (Ap-
plied Biosystems, Foster City, CA). Gene expression analysis was performed by
RT-PCR using TaqMan gene expression assays (Applied Biosystems), including
18S and glyceraldehyde-3-phosphate dehydrogenase probe and primers for
housekeeping measurements.
AMPK activity and markers of oxidative stress. AMPK activity was mea-
sured in tissue lysates as previously described (33). Malondialdehyde content
was determined spectrophotometrically using BIOXTECH MDA-586 assay kit
(Oxis Research, Portland, OR).
Statistics. Data are reported as mean 6 SEM. Comparisons between data
from multiple treatment groups were made using factorial ANOVA, followed
by Newman-Keuls post hoc analysis. To speciﬁcally examine differences be-
tween WT and Tg mice, data were analyzed using the Mann-Whitney U test.
Statistical signiﬁcance was accepted at P , 0.05.
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RESULTS
Muscle ceramide is reduced in SphK1 Tg mice. SphK1
Tg mice were indistinguishable from WT littermates with
respect to body mass or fat mass (Table 1). We screened
a number of metabolic tissues and only observed increased
SphK activity in skeletal muscle (Fig. 1A). In addition, S1P
levels tended to increase in muscle of SphK1 Tg mice rel-
ative to WT, but this was not statistically different (Fig. 1B).
Furthermore, sphingosine content (Fig. 1C) was not altered,
but the S1P-to-sphingosine ratio tended to be reduced in
SphK1 Tg mice (0.61 6 0.12) compared with WT mice
(1.45 6 0.16), although this was not statistically signiﬁcant
(P . 0.05). However, ceramide was reduced in the quadri-
ceps and soleus, but not in WAT or liver (Fig. 1D). Despite
these changes, when fed a chow diet, SphK1 Tg mice did
not show any differences in fasting plasma glucose, insulin,
FFAs, triglycerides, ceramides, or S1P compared with WT
mice (Table 1). In addition, glucose tolerance was not dif-
ferent when compared with WT mice (Fig. 1E).
Because we only studied mice overexpressing SphK1,
the possibility existed that SphK2 may play a role in me-
tabolism. To our knowledge, a Tg mouse does not exist for
SphK2, but to rule out the possibility that this isoform
plays a role, we transiently overexpressed SphK2 in skel-
etal muscle using in vivo electroporation. SphK2 over-
expression had no effect on intramuscular lipid content
(Supplementary Fig. 1A–C), suggesting that SphK1, but not
SphK2, plays a role in regulating muscle ceramide levels;
therefore, further studies were focused entirely on SphK1.
SphK1 Tg mice are protected from HFD-induced
ceramide accumulation. The HFD increased body mass
and fat mass, as well as fasting plasma glucose, insulin,
triglycerides, and S1P in both strains of mice, but there
were no differences between SphK1 Tg and WT littermates
(Table 1). In WT mice, the HFD increased total muscle
ceramide by ;40% (4456 48 vs. 611 6 50 pmol/mg protein
for chow and HFD WT mice, respectively; P, 0.05; Fig. 2A
and B). Importantly, however, this effect was ameliorated
in SphK1 Tg mice (Fig. 2A) to an extent where muscle
from these mice was resistant to the effects of the HFD
with respect to ceramide accumulation (Fig. 2B). Despite
these effects, neither fat-feeding nor SphK1 over-
expression affected the expression of acid ceramidase
(Supplementary Fig. 6). Similar to our ﬁndings in chow-fed
mice, muscle S1P and sphingosine were not altered in
SphK1 Tg relative to WT mice (Fig. 2C and D).
Consistent with a reduction in ceramide, overexpression
of SphK1 resulted in a reduction in C18:0 sphingomyelin
(Supplementary Fig. 2A), the most predominant species in
muscle, and in total sphingomyelin levels (Fig. 2E). In ad-
dition, a number of sphingomyelin species were increased in
response to the HFD (Supplementary Fig. 2A). The HFD also
increased muscle DAG (Fig. 2F and Supplementary Fig. 2B)
and TAG (Fig. 2G), which was independent of the genetic
strain of mice. Interestingly, despite the increase in DAG
with an HFD, the membrane-to-cytosol ratio of PKCu was
not altered (Supplementary Fig. 3). Although S1P can
be hydrolyzed by S1P lyase to form hexadecanol and
phosphoethanolamine, of which the later can be used for
the biosynthesis of PE, S1P lyase expression and activity in
skeletal muscle is almost undetectable (34); thus, the rel-
evance of this pathway in muscle is questionable. None-
theless, we analyzed muscle PE content to determine
whether SphK1 overexpression altered this lipid. In addi-
tion, it has recently been suggested that the ratio between
PC and PE is altered as a consequence of obesity, resulting
in cellular stress (35). Therefore, we also analyzed the PC
content. However, in this model, neither diet nor SphK1
overexpression affected PE (Fig. 2H) or PC (Fig. 2H)
levels in muscle.
HFD-induced muscle insulin resistance is ameliorated
in SphK1 Tg mice. Because HFD-induced increase in
muscle ceramide accumulation was prevented in SphK1 Tg
mice, we examined whether these mice would have im-
proved glucose homeostasis. Initial studies showed that
glucose tolerance was improved in SphK1 Tg mice fed an
HFD compared with WT mice (Fig. 3A). Ex vivo glucose
uptake assays revealed no differences in chow-fed WT or
SphK1 Tg mice; however, consistent with our glucose
tolerance data, insulin-stimulated glucose uptake was en-
hanced in HFD SphK1 Tg mice compared with HFD WT
mice (Supplementary Fig. 4A and B). Although insulin
sensitivity was improved in HFD SphK1 Tg mice, it was not
restored to those levels observed in chow-fed mice (Sup-
plementary Fig. 3A and B).
Given these observations, we performed hyperinsu-
linemic, euglycemic clamp studies in SphK1 Tg and WT
mice fed the HFD. Glucose levels were successfully clamped
at basal levels in both strains (Fig. 3B), and no differences
were observed in plasma insulin or FFA levels during the
clamp (Table 1). Basal rates of glucose production were
not different between strains (Fig. 3D). The GIR during the
TABLE 1
Characteristics of chow- and HFD-fed WT and SphK1 Tg mice
Chow HFD
WT n SphK1 Tg n WT n SphK1 Tg n
Body mass (g)* 30.4 6 0.9 15 31.0 6 1.1 10 37.0 6 0.9 22 36.8 6 1.1 17
Fat mass (g)* 3.2 6 0.4 15 3.0 6 0.6 10 10.8 6 0.7 22 11.2 6 0.8 17
Fasting blood glucose (mmol/L)* 9.6 6 0.4 15 10.5 6 0.3 10 12.2 6 0.5 15 11.9 6 0.6 13
Fasting plasma insulin (ng/mL)* 0.50 6 0.05 7 0.47 6 0.04 8 2.48 6 0.34 14 2.23 6 0.31 8
15-min IPGTT plasma insulin (ng/mL) 0.77 6 0.13† 7 1.22 6 0.14† 8 2.75 6 0.37 14 2.21 6 0.35 8
Clamp plasma insulin (ng/mL) ND ND 6.55 6 0.83 5 5.41 6 0.76 6
Fasting plasma FFA (mmol/L) 0.59 6 0.10 12 0.70 6 0.12 9 0.66 6 0.06 5 0.61 6 0.03 6
Clamp plasma FFA (mmol/L) ND ND 0.44 6 0.07 5 0.40 6 0.02 6
Fasting plasma triglyceride (mmol/L)* 0.35 6 0.03 8 0.42 6 0.05 5 0.50 6 0.04 10 0.58 6 0.05 10
Fasting plasma ceramide (mmol/L) 1.99 6 0.28 13 2.34 6 0.41 10 2.59 6 0.19 19 2.60 6 0.16 16
Fasting plasma S1P (mmol/L)* 0.20 6 0.08 6 0.10 6 0.06 4 0.47 6 0.06 5 0.52 6 0.05 5
Data are mean6 SEM. IPGTT, intraperitoneal glucose tolerance test; ND, not determined. *P, 0.05 main effect for diet; †P, 0.05 vs. fasting.
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clamp was markedly higher in SphK1 Tg compared with
WT mice (Fig. 3C). This was primarily due to improved
muscle insulin sensitivity because IS-Rd was higher in
SphK1 Tg compared with WT mice (Fig. 3E). In contrast,
the suppression of hepatic glucose production during the
clamp was comparable between SpK1 Tg and WT mice
(Fig. 3F), indicating that hepatic insulin action was not
affected by SphK1 overexpression in muscle. This was
expected because the HFD-induced increase in liver lipids
(Supplementary Fig. 5A–C) was not different when com-
paring SphK1 Tg with WT mice. Tissue-speciﬁc glucose
uptake (Rg9) during the clamp was augmented in hind limb
muscle from SphK1 Tg mice (EDL, tibialis anterior, and
quadriceps), but not in WAT (Fig. 3G). We also examined
the effect of SphK1 overexpression on Akt phosphoryla-
tion in isolated EDL muscles. Insulin-stimulated Akt
phosphorylation was increased in HFD SphK1 Tg mice
compared with HFD WT mice (Fig. 3H–J).
SphK1 Tg mice are protected from HFD-induced JNK
activation. The phosphorylation of IKK-b was neither af-
fected by diet nor genotype (Fig. 4A). In contrast, the HFD
induced a signiﬁcant increase in JNK phosphorylation, but
this was attenuated in SphK1 Tg mice (Fig. 4B). We also
examined whether proinﬂammatory cytokines or markers
of macrophage inﬁltration were affected by diet or mouse
genetic strain in skeletal muscle. Although F4/80 mRNA
was increased by the HFD, no such effect was seen for
interleukin 6 or tumor necrosis factor-a expression. The
expression of these genes was unaffected by SphK1 over-
expression, irrespective of diet (Supplementary Fig. 6). To
conﬁrm the in vivo results, we used an alternative model
system, high concentrations of the saturated FA palmitate,
to activate JNK in muscle. Isolated soleus muscles from
WT and SphK1 Tg mice were incubated in the presence of
low-dose (control; 0.5 mmol/L) and high-dose (2.0 mmol/L)
palmitate. Incubation of high-dose palmitate uniformly in-
creased the accumulation of ceramide species, as well as
total ceramide, but this increase was blunted when the
skeletal muscle of SphK1 Tg was compared with WT mice
(Fig. 4C). In this model, the palmitate-induced phosphoryla-
tion of JNK was also markedly attenuated in muscle from
SphK1 Tg mice (Fig. 4D).
Overexpression of SphK1 does not alter markers of
angiogenesis, oxidative stress, or AMPK activity. Be-
cause Sphk1/S1P has been implicated in regulating angio-
genesis (23), oxidative stress (24), and AMPK activity (36),
it is possible that any one of these factors could be affected
by SphK1 overexpression and inﬂuence muscle insulin
sensitivity. Therefore, the expression of numerous markers
of angiogenesis was determined, including cluster of dif-
ferentiation (CD) 31, platelet-derived growth factor (PDGF),
and vascular endothelial growth factor (VEGF). The ex-
pression of CD31 was unaffected by diet or genotype,
whereas PDGF was reduced with the HFD, and VEGF ex-
pression was lower in muscle of SphK1 Tg mice (Supple-
mentary Fig. 6). The content of malondialdehyde, a marker
of tissue oxidative stress, was not altered by the HFD or
SphK1 overexpression (Supplementary Fig. 7A). Further-
more, muscle AMPK activity was similar in all groups
studied (Supplementary Fig. 7B).
DISCUSSION
Ceramide is a potent lipid-signaling molecule that can
cause insulin resistance by impairing activation of the in-
sulin-signaling pathway. Moreover, preventing ceramide
accumulation by inhibiting de novo ceramide synthesis
protects against insulin resistance (9,10). It is well known
FIG. 1. Phenotypic data from chow-fed WT and SphK1 Tg mice. A: SphK1 activity in muscle, WAT, and liver (WT n = 8; SphK1 Tg n = 5). B: Muscle
S1P content (WT n = 7; SphK1 Tg n = 6). C: Muscle sphingosine content (WT n = 7; SphK1 Tg n = 6). D: Ceramide levels in quadriceps (Quad) (WT
n = 7; SphK1 Tg n = 5), soleus (WT n = 7; SphK1 Tg n = 6), WAT (WT n = 10; SphK1 Tg n = 10), and liver (WT n = 8; SphK1 Tg n = 5). E: Glucose
tolerance curves (WT n = 15; SphK1 Tg n = 10). Data are mean 6 SEM. **P < 0.01 vs. WT.
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that SphK1 prevents ceramide accumulation by promoting its
metabolism into S1P, but to date, the role of SphK1 in the
etiology of obesity and insulin resistance has not been di-
rectly examined. Here, we provide novel evidence that SphK1
is an important enzyme that regulates ceramide metabolism
and insulin sensitivity in skeletal muscle. These ﬁndings
highlight that in addition to inhibiting ceramide synthesis,
targeting pathways to enhance ceramide degradation may
be beneﬁcial in treating muscle insulin resistance.
Several hypotheses have been proposed to deﬁne the
molecular pathways that impair insulin action. Insulin re-
sistance is associated with ectopic lipid deposition in liver
and muscle (2); moreover, the accumulation of deleterious
lipids, such as DAG (5) and ceramide (10), dysregulate in-
sulin action directly (6) or indirectly via the activation of
serine threonine kinases such JNK (7). Data from the current
study, at least with respect to SphK1 overexpression, suggest
that ceramide accumulation and JNK activation in muscle
are involved in HFD-induced insulin resistance in mice.
When SphK1 Tg mice were fed the HFD, ceramide levels
were not increased above those observed in chow-fed Tg
animals. These results were accompanied by improved
whole-body and skeletal muscle insulin sensitivity (Fig. 3A–F
and Supplementary Fig. 4), improved insulin-stimulated Akt
phosphorylation (Fig. 3G–I), and an attenuated JNK phos-
phorylation in muscle (Fig. 4). Together, these data suggest
that overexpression of SphK1 in skeletal muscle prevents
ceramide accumulation and bioactivity, which improves in-
sulin action, in part, by improving insulin signaling and pre-
venting JNK phosphorylation.
Overexpression of SphK1 may be expected to increase
S1P levels. In the current study, we did not detect an in-
crease in intramuscular S1P content in SphK1 Tg mice
(Fig. 1B, Fig. 2C). Although somewhat unexpected, these
ﬁndings are similar to those of Takuwa et al. (24), who
found that tissue S1P was only modestly increased in
SphK1 Tg mice with high-level overexpression, whereas in
mice with low-level overexpression, S1P was not different
to WT mice. This suggests that any increase in S1P pro-
duction caused by overexpressing SphK1 is balanced by
S1P breakdown (23). Nonetheless, these ﬁndings have
important implications for the current study because they
suggest that SphK1 overexpression in these circumstances
improves metabolic homeostasis by reducing ceramide
accumulation per se and not via any effect due to an in-
crease in intracellular S1P.
FIG. 2. Muscle lipid levels in chow-fed and HFD-fed WT and SphK1 Tg mice. A: Ceramide levels (chow WT n = 7; chow SphK1 Tg n = 5; HFD WT n =
15; HFD SphK1 Tg n = 15). B: Fold change in total ceramide content (data expressed relative to chow group of the same genotype; n = 15). C: S1P
content in muscle of HFD-fed WT (n = 8) and SphK1 Tg mice (n = 7). D: Muscle sphingosine content (WT n = 8; SphK1 Tg n = 7). E: Muscle
sphingomyelin levels (chow WT n = 5; chow SphK1 Tg n = 5; HFD WT n = 7; HFD SphK1 Tg n = 7). F: Muscle DAG proﬁle (chow WT n = 5; chow
SphK1 Tg n = 5; HFD WT n = 7; HFD SphK1 Tg n = 7). G: Muscle TAG content (chow WT n = 6; chow SphK1 Tg n = 7; HFD WT n = 10; HFD SphK1 Tg
n = 8). H: PE levels (chow WT n = 5; chow SphK1 Tg n = 5; HFD WT n = 7; HFD SphK1 Tg n = 7). I: PC levels (chow WT n = 5; chow SphK1 Tg n = 5;
HFD WT n = 7; HFD SphK1 Tg n = 7). Data are mean 6 SEM. *P < 0.05 vs. wild type. †Main effect for genotype, P < 0.05. ‡Main effect for diet,
P < 0.05.
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Although our study reveals an important role for SphK1
in regulating muscle ceramide, we cannot discount the
possibility that overexpression of SphK1 altered the ac-
tivity of other enzymes involved in sphingolipid metabo-
lism. In this regard, sphingomyelin levels were lower in
muscle from SphK1 Tg mice. However, rather than being
mediated by alterations in enzyme activity, this effect may
simply be driven by the reduction in ceramide itself. In
support of such a precursor relationship is the fact that the
C18:0 species of both ceramide and sphingomyelin were
reduced by SphK1 overexpression. Nonetheless, because
sphingolipid enzymes, such as serine palmitoyltransferase,
ceramidase, and sphingomyelinase, are regulated by fac-
tors such as exercise training (37) and HFD (38), it is
possible that the activity of these enzymes was altered in
SphK1 Tg mice, which may, in part, contribute to the ob-
served effects on muscle ceramide metabolism.
Previous studies have implicated SphK1 in playing a role
in regulating muscle blood ﬂow and angiogenesis (23),
factors that could alter muscle insulin sensitivity. Our data
showing enhanced insulin-stimulated glucose uptake ex
vivo (Supplementary Fig. 4) suggests that the effects of
SphK1 overexpression on muscle insulin sensitivity are
independent of changes in blood ﬂow and angiogenesis. In
this ex vivo system, differences in muscle capillarization and
blood ﬂow are circumvented as substrate delivery occurs via
diffusion from the incubation medium. Furthermore, we
determined the expression of a number of markers of an-
giogenesis in muscle. Although CD31 expression was un-
affected by diet or genotype, PDGF was reduced with the
HFD and VEGF was lower in muscle of SphK1 Tg mice.
Taken together, these data do not support a role for in-
creased angiogenesis or blood ﬂow contributing to the im-
provement in insulin action in the HFD SphK1 Tg mice.
In addition to ceramide, DAG accumulation is associ-
ated with muscle insulin resistance (4,5). Overexpression
of SphK1 reduced ceramide levels, but the HFD-induced
increase in DAG was unaffected. Interestingly, the im-
provement in insulin-stimulated glucose uptake in HFD
SphK1 Tg mice was not sufﬁcient to restore insulin sen-
sitivity to chow-fed levels (Supplementary Fig. 4). Thus, it
is possible that DAG mediated the residual insulin re-
sistance in fat-fed SphK1 Tg mice. Although the mecha-
nism by which DAG causes insulin resistance is not
completely understood, it is possible that activation of
PKC isoforms is involved. We have previously shown that
fat-feeding in rats increases muscle DAG and leads to an
increase in the membrane-to-cytosol ratio of PKCu (27)
and that preventing DAG accumulation by increasing FA
oxidation blocks the redistribution of PKCu to the mem-
brane; however, we did not detect any differences in the
localization of PKCu in the current study. These ﬁndings
suggest that other PKC isoforms not analyzed, such as
PKCd and PKC´, may play a role in DAG-mediated insulin
resistance or implicate PKC-independent mechanisms.
Regardless, our data indicate that ceramide and DAG are
both likely to contribute to the development of insulin
resistance in muscle.
In summary, our data reveal that SphK1 is a key enzyme
that reduces the accumulation of muscle ceramide in
FIG. 3. Glucose tolerance and insulin sensitivity is enhanced in SphK1 Tg mice fed an HFD. A: Blood glucose levels during a glucose tolerance test
in HFD-fed WT (n = 22) and SphK1 Tg (n = 17) mice. B: Blood glucose levels during the hyperinsulinemic, euglycemic clamp (WT n = 5; SphK1 Tg n =
6). C: Glucose infusion rate (WT n = 5; SphK1 Tg n = 6). D: Basal rates of endogenous glucose Ra (EndoRa) (WT n = 5; SphK1 Tg n = 6). E: Insulin-
stimulated glucose Rd (WT n = 5; SphK1 Tg n = 6). F: Percent suppression of EndoRa (WT n = 5; SphK1 Tg n = 6). G: Tissue glucose uptake (WT n =
5; SphK1 Tg n = 6). H: Immunoblot of pAkt serine (ser) 473 in basal and insulin-stimulated EDL muscles ex vivo (n = 8 for each group).
I: Quantiﬁcation of pAkt ser473 (n = 8 for each group). J: Fold change in pAkt ser473 under insulin-stimulated conditions. Data are mean 6 SEM;
n = 17–22 for the glucose tolerance data (n = 8 for each group). *P < 0.05 vs. WT; **P < 0.01 vs. WT. TA, tibialis anterior; Quad, quadriceps.
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conditions of lipid oversupply. This is important because
ceramide has previously been shown to activate JNK
and inhibit insulin signaling, which both contribute to de-
creased insulin action. These data identify SphK1 as an
important regulator of lipid partitioning in skeletal muscle,
thereby highlighting the potential for targeting pathways to
enhance ceramide degradation for the prevention and/or
treatment of obesity-induced muscle insulin resistance.
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